7 Einträge gefunden

1. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

   1. Richardson, Paul G
   2. Schjesvold, Fredrik
   3. Weisel, Katja
   4. Moreau, Philippe
   5. Anderson, Larry D
   6. White, Darrell
   7. Rodriguez-Otero, Paula

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR

   1. Weisel, Katja
   2. Mateos, Maria-Victoria
   3. Gay, Francesca
   4. Delforge, Michel
   5. Cook, Gordon
   6. Szabo, Zsolt
   7. Desgraz, Renaud

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

   1. Dimopoulos, Meletios
   2. Weisel, Katja
   3. Moreau, Philippe
   4. Anderson, Larry D
   5. White, Darrell
   6. San-Miguel, Jesus
   7. Sonneveld, Pieter

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

   1. Avet-Loiseau, Hervé
   2. San-Miguel, Jesus
   3. Casneuf, Tineke
   4. Iida, Shinsuke
   5. Lonial, Sagar
   6. Usmani, Saad Z
   7. Spencer, Andrew

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma

   1. Weisel, Katja
   2. Dimopoulos, Meletios
   3. Moreau, Philippe
   4. Yagci, Munci
   5. Larocca, Alessandra
   6. Kanate, Abraham S
   7. Vural, Filiz

   2020 - Forschungsinformationssystem des UKE
6. Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis

   1. Dimopoulos, Meletios A
   2. Niesvizky, Ruben
   3. Weisel, Katja
   4. Siegel, David S
   5. Hajek, Roman
   6. Mateos, María-Victoria
   7. Cavo, Michele

   2020 - Forschungsinformationssystem des UKE
7. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

   1. Dimopoulos, Meletios A
   2. Lonial, Sagar
   3. White, Darrell
   4. Moreau, Philippe
   5. Weisel, Katja
   6. San-Miguel, Jesus
   7. Shpilberg, Ofer

   2020 - Forschungsinformationssystem des UKE